A Phase 1b/2 Study of the ROR1-Targeting Monoclonal Antibody, Cirmtuzumab (UC-961), and the Bruton Tyrosine Kinase Inhibitor, Ibrutinib, in Patients With B-Cell Lymphoid Malignancies
Latest Information Update: 01 Oct 2024
At a glance
- Drugs Ibrutinib (Primary) ; Zilovertamab (Primary)
- Indications Chronic lymphocytic leukaemia; Mantle-cell lymphoma; Marginal zone B-cell lymphoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Oncternal Therapeutics, Inc.
- 27 Sep 2024 Status changed from active, no longer recruiting to completed.
- 12 Sep 2024 Planned End Date changed from 30 Aug 2024 to 30 Sep 2024.
- 12 Sep 2024 Planned primary completion date changed from 30 Aug 2024 to 30 Sep 2024.